Targeting HPV-16 antigens to the endoplasmic reticulum induces an endoplasmic reticulum stress response. 2019

David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
Departamento de Histología, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Madero y Aguirre Pequeño s/n Mitras Centro, 66460, Monterrey, Nuevo León, México.

Very promising results have been observed with a deoxyribonucleic acid (DNA) vaccine based on human papillomavirus type-16 (HPV-16) antigen retention and delivery system in the endoplasmic reticulum (ER). However, the mechanism by which these antigens are processed once they reach this organelle is still unknown. Therefore, we evaluated whether this system awakens a stress response in the ER. Different DNA constructs based on E6 and E7 mutant antigens fused to an ER signal peptide (SP), a signal for retention in the ER (KDEL), or both signals (SPK), were transfected into HEK-293 cells. Overexpression of E6 and E7 antigens targeted to the ER (SP, and SPK constructs) induced ER stress, which was indicated by an increase of the ER-stress markers GRP78/BiP and CHOP. Additionally, the ER stress response was mediated by the ATF4 transcription factor, which was translocated into the nucleus. Besides, the overexpressed antigens were degraded by the proteasome. Through a cycloheximide-chase assay, we demonstrated that when both protein synthesis and proteasome were inhibited, the overexpressed antigens were degraded. Interestingly, when proteasome was blocked autophagy was increased and the ER stress response decreased. Taken together, these results indicate that the antigens are initially degraded by the ERAD pathway, and autophagy degradation pathway can be induced to compensate the proteasome inhibition. Therefore, we provided a new insight into the mechanism by which E6 and E7 mutant antigens are processed once they reach the ER, which will help to improve the development of more effective vaccines against cancer.

UI MeSH Term Description Entries
D004721 Endoplasmic Reticulum A system of cisternae in the CYTOPLASM of many cells. In places the endoplasmic reticulum is continuous with the plasma membrane (CELL MEMBRANE) or outer membrane of the nuclear envelope. If the outer surfaces of the endoplasmic reticulum membranes are coated with ribosomes, the endoplasmic reticulum is said to be rough-surfaced (ENDOPLASMIC RETICULUM, ROUGH); otherwise it is said to be smooth-surfaced (ENDOPLASMIC RETICULUM, SMOOTH). (King & Stansfield, A Dictionary of Genetics, 4th ed) Ergastoplasm,Reticulum, Endoplasmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000091342 Endoplasmic Reticulum Chaperone BiP An ENDOPLASMIC RETICULUM specific chaperone of the HSP70 family. They are involved in folding and oligomerization of secreted and membrane proteins and ENDOPLASMIC RETICULUM STRESS related UNFOLDED PROTEIN RESPONSE. Binding-immunoglobulin Protein Molecular Chaperone,Glucose Regulated Protein 78 kDa,Grp78,HSPA5 Protein,Heat-Shock Protein 5,Molecular Chaperone BiP,Molecular Chaperone GRP78,BiP, Molecular Chaperone,Binding immunoglobulin Protein Molecular Chaperone,GRP78, Molecular Chaperone,Heat Shock Protein 5,Protein, HSPA5
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D046988 Proteasome Endopeptidase Complex A large multisubunit complex that plays an important role in the degradation of most of the cytosolic and nuclear proteins in eukaryotic cells. It contains a 700-kDa catalytic sub-complex and two 700-kDa regulatory sub-complexes. The complex digests ubiquitinated proteins and protein activated via ornithine decarboxylase antizyme. 20S Proteasome,Ingensin,Macropain,Macroxyproteinase,Multicatalytic Endopeptidase Complex,Multicatalytic Proteinase,Prosome,Proteasome,Complex, Multicatalytic Endopeptidase,Complex, Proteasome Endopeptidase,Endopeptidase Complex, Multicatalytic,Endopeptidase Complex, Proteasome,Proteasome, 20S,Proteinase, Multicatalytic
D052162 Human papillomavirus 16 A type of ALPHAPAPILLOMAVIRUS especially associated with malignant tumors of the CERVIX and the RESPIRATORY MUCOSA. HPV 16,HPV16,Human papillomavirus - 16,Human papillomavirus type 16,human papillomavirus type 16 HPV 16,human papillomavirus type 16 HPV16,HPV-16,HPV 16s,HPV16s
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell
D059865 Endoplasmic Reticulum Stress Various physiological or molecular disturbances that impair ENDOPLASMIC RETICULUM function. It triggers many responses, including UNFOLDED PROTEIN RESPONSE, which may lead to APOPTOSIS; and AUTOPHAGY. Stress, Endoplasmic Reticulum,Endoplasmic Reticulum Stresses,Reticulum Stress, Endoplasmic,Reticulum Stresses, Endoplasmic,Stresses, Endoplasmic Reticulum

Related Publications

David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
December 2009, European journal of pharmacology,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
September 2021, Revista espanola de cardiologia (English ed.),
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
July 2015, Analytical and bioanalytical chemistry,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
March 2012, Molecular cancer research : MCR,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
January 2011, Current pharmaceutical design,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
April 2013, Toxicology and applied pharmacology,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
December 2008, Molecular pharmacology,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
July 2008, Nature,
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
October 2013, Aquatic toxicology (Amsterdam, Netherlands),
David H Martínez-Puente, and José J Pérez-Trujillo, and Yolanda Gutiérrez-Puente, and Humberto Rodríguez-Rocha, and Aracely García-García, and Odila Saucedo-Cárdenas, and Roberto Montes-de-Oca-Luna, and María J Loera-Arias
November 2006, Molecular and cellular biology,
Copied contents to your clipboard!